Acumen top line data releasedhttps://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-positive-topline-results-first
Looks good at first glance. Perhaps still some room for ARIA-E reduction, but 7% at 25 mg/kg seems significantly lower than aducanumab or leqembi
Looks like they had good target engagement at 25 mg/kg and would not expect to need higher doses
ARIA-E at 60 mg/kg was higher, 14%
They provide plaque reduction data as well, though plaque is not the target. Perhaps that is due to reduction in plaque formation due to reduction in toxic Ab oligomers? If I recall, previous studies of aducanumab which targets plaque more tied some of that to ARIA-E risk due to dislocation of existing plaque from weak arterial surfaces
What does this all mean for PMN? Supports core hypothesis and approach (great supporting data!) Some opportunity for incremental improvement over this new competition.
Why not get in the mix Boston Group? PMN310 could be even better! And the market is massive!